S-ClassAbout S-Class
E
ETONAI Stock Diagnostic Report
Eton Pharmaceuticals jumps on strong Q2 print, 2026 guidance
Eton Pharmaceuticals announced strong second-quarter results and a revenue forecast for 2026, causing its stock to surge 25% in pre-market trading.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$40.79999923706055Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support37.00
Near-Term Resistance50.18
02
FUNDAMENTALS
Financial & Fundamental Analysis
With the strong performance in the second quarter, it demonstrated fundamental growth potential by presenting an annual revenue of over $145 million for 2026 and an adjusted EBITDA margin of over 35%.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $40.80 is positioned above the 20-day low support level of $37.00, and we should monitor the potential for an increase towards the 20-day high resistance level around $50.18 as trading volume increases following a short-term excessive decline.
Support37.00
Resistance50.18
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The main driver behind the 25% surge in the pre-market is the strong performance and the aggressive upward revision of the 2026 guidance, along with ongoing pipeline expansion momentum, including the acquisition of the pediatric vascular tumor pipeline (ASN-001) and the submission of supplemental documents to the FDA.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-14)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.